PHusis Therapeutics Inc — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Oncogenic KRAS is found in 25% of patient tumors acro
PHusis Therapeutics Inc — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $225,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- TX
- Period
- —
Description
DESCRIPTION (provided by applicant): Oncogenic KRAS is found in 25% of patient tumors across many cancer types. Despite extensive effort since its discovery over 30 years ago there is still no effective treatment for KRAS tumors. An estimated 350,000 patients in the US in 2013 will be diagnosed with mutated KRAS in their tumor, and many will die of their disease. Mutated KRAS plays a critical role in driving tumor growth and resistance to therapy. Its effects are so powerful that it overrides the activity of many of the new molecularly targeted signaling drugs being developed for cancer. Thus, finding new agents that inhibit the effects of mutated KRAS is one of the most important unmet medical needs in cancer today. Mutated KRAS as a target also presents anuntapped business opportunity because of the large number of patients that could benefit from an effective inhibitor, used alone or in combination with molecularly targeted therapies from which the patients are currently excluded. PHusis Therapeutics